Semaglutide Shows Promise for Non-Diabetic Chronic Kidney Disease in Landmark SMART Trial

Exciting news emerged from Kidney Week 2024 as the landmark SMART trial unveiled promising results for semaglutide (Ozempic/Wegovy) in treating non-diabetic chronic kidney disease (CKD). Presented simultaneously in Nature Medicine, the study suggests semaglutide could offer a new therapeutic avenue beyond its established role in diabetes management.

The SMART Trial Findings

The placebo-controlled, double-blind trial, led by Hiddo Heerspink, PhD, PharmD, of the University of Groningen, evaluated the impact of semaglutide 2.4 mg on patients with obesity and non-diabetic CKD. Key findings include:

• A significant 52.1% reduction in urine albumin-to-creatinine ratio (UACR) in the semaglutide arm compared to placebo.
• Dose-dependent effects, with higher doses potentially leading to amplified albuminuria reduction.
• Sustained effects of semaglutide on albuminuria even weeks after treatment cessation.
• Weight loss of -9.1 kg and a reduction in waist circumference of -6.2 kg in the semaglutide group.

Importantly, the study observed no significant difference in creatinine-based estimated glomerular filtration rate (Cr-eGFR) between the groups.

Beyond Albuminuria: Broader Implications for Kidney Health

The SMART trial’s findings extend beyond albuminuria reduction. Researchers observed potential benefits in other areas of kidney health, including:

• Anti-inflammatory effects of semaglutide.
• Potential for long-term GFR protection.
• Improved blood pressure control.
• Reduced levels of B-type natriuretic peptide (BNP), a marker of cardiac stress.

These findings highlight semaglutide’s versatility and potential to improve outcomes across multiple aspects of kidney and cardiovascular health.

Future Directions

While the SMART trial marks a significant advancement, further research is needed to fully elucidate semaglutide’s role in non-diabetic CKD. Future studies will focus on:

• Long-term safety and efficacy of semaglutide in this population.
• Optimizing dosing regimens for different patient subgroups.
• Exploring the drug’s potential in other nephrological conditions.

Stay Informed about Kidney Health Developments

The field of nephrology is continuously evolving. For the latest research updates and insights into managing CKD, visit our website and subscribe to our newsletter.